Case of class II lupus nephritis with nephrotic features in the context of belimumab: Intersecting clinical challenge with academic initiative to emphasize social barriers in care

Lupus nephritis is a severe complication of systemic lupus erythematosus that can cause significant kidney damage, leading to symptoms such as proteinuria, hematuria, and renal failure. If not managed promptly, it can progress to chronic kidney disease or even end-stage renal disease. Early diagnosis and treatment are vital to prevent such outcomes. While traditional treatments focus on immunosuppressive therapies, the introduction of belimumab offers a new treatment approach. Kidney biopsies play a crucial role in diagnosing and classifying lupus nephritis, helping guide appropriate treatment. Class II lupus nephritis typically requires supportive care, but more severe cases demand aggressive therapy. Noncompliance with treatment can worsen the condition, highlighting the need to address social challenges that impact patient care and adherence. We hereby report a 19-year-old female with systemic lupus erythematosus and nephrotic-range proteinuria, diagnosed with Class II lupus nephritis shortly after initiating belimumab, highlighting the social challenges impacting her care and follow-up. We hereby report a 19-year-old female known with systemic lupus erythematosus with nephrotic-range proteinuria and Class II lupus nephritis. Diagnosed shortly after belimumab, and highlighting the social challenges in her care and follow-up.

• Publication year

  2025

• Venue

  SAGE Open Medical Case Reports

• Publication date

  2025-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2050313X251336061PMID 40371310PMCID 12075971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus

  2023cited by this paper
• Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.

  2022cited by this paper
• 10 Years of belimumab experience: What have we learnt?

  2021cited by this paper
• Lupus nephritis

  2020cited by this paper
• Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

  2020influential reference
• Addressing the social determinants of health at the local level: Opportunities and challenges

  2018cited by this paper
• Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.

  2018cited by this paper
• Redefining lupus nephritis: clinical implications of pathophysiologic subtypes

  2017cited by this paper
• Classifying Lupus Nephritis: An Ongoing Story

  2014cited by this paper
• The social determinants of health: coming of age.

  2011cited by this paper
• The importance of addressing social determinants of health at the local level: the case for social capital.

  2011cited by this paper
• Belimumab

  2011cited by this paper
• Abstracts of the 9th International Congress on SLE. June 24-27 2010. Vancouver, Canada.

  2010cited by this paper
• The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years.

  2007cited by this paper
• Lupus nephritis.

  1999cited by this paper
• Lupus Nephritis

  1959cited by this paper

• No citing papers are available for this paper.